BullScope
  • Home
  • Market News
  • Bargains & Bubbles
  • Expectations Audits
  • Research Notes
  • Said vs. Filed
  • The Economy
  • Evidence Sheets
  • Research Terminal
No Result
View All Result
SUBSCRIBE
BullScope
  • Home
  • Market News
  • Bargains & Bubbles
  • Expectations Audits
  • Research Notes
  • Said vs. Filed
  • The Economy
  • Evidence Sheets
  • Research Terminal
No Result
View All Result
BullScope
No Result
View All Result
Home Evidence Sheets

Evidence Sheet: Amazon (AMZN)

Moe Alsumidaie, MBA, MSF by Moe Alsumidaie, MBA, MSF
August 4, 2026
in Evidence Sheets
0
74
SHARES
1.2k
VIEWS
Share on XShare on LinkedInShare on Facebook

This is the standing evidence sheet for Amazon (AMZN): the yardsticks BullScope computes from official SEC filings and market prices. It refreshes whenever a new edition of our research is published, and it is impersonal by design, every reader sees the same page. Nothing here is investment advice; it is the evidence, organized.

The price tag: what buyers pay per dollar of profit

Today the market pays about $32.7 for each $1 of Amazon’s annual profit (a price-to-earnings ratio of 32.7). Across its own past decade the typical price tag was 41.5, which puts today at roughly the 12th percentile of the company’s own history.

The tape: what the stock itself has done

  • Last price: $284.02 · 0% below its 52-week high
  • Past 6 months: +18.7% · past 12 months: +21.3%
  • Day-to-day temperament: jumpy (annualized volatility 35%)

The filed record: straight from the annual reports

Fiscal year Revenue Growth Operating margin EPS
FY2021 $469.8B , 5.3% $64.81
FY2022 $514.0B +9.4% 2.4% $-0.27
FY2023 $574.8B +11.8% 6.4% $2.9
FY2024 $638.0B +11.0% 10.8% $5.53
FY2025 $716.9B +12.4% 11.2% $7.17

The road ahead: filed results vs published expectations

FY2023A FY2024A FY2025A FY2026E FY2027E
Net sales ($B) 574.8 638.0 716.9 775 to 810 845 to 920
Net sales growth (%) +11.9 +11.0 +12.4 8 to 13 9 to 14
Operating margin (%) 6.4 10.8 11.2 11.0 to 12.5 11.5 to 13.5
GAAP Diluted EPS ($) 2.90 5.53 7.17 7.30-10.30 7.39-11.39
Adjusted EPS (non-GAAP, excl. Anthropic MTM) , , , 7.50 to 9.50 8.50 to 11.00

Columns marked A are actual filed results; E columns are the published consensus ranges the current price is being weighed against.

The four gauges: from the latest edition

Can it keep growing?: 72/100 (higher is better)Can it keep growing?72higher is betterCompetition pressure: 68/100 (higher is worse)Competition pressure68higher is worseLegal & political risk: 62/100 (higher is worse)Legal & political risk62higher is worseCost & margin risk: 58/100 (higher is worse)Cost & margin risk58higher is worse
Hover any bar for the reading. Scored 0–100 in the latest edition; green is favorable on every bar.

BullScope coverage of Amazon

  • Amazon’s Cloud Is Printing Money. The Question Is What It Costs to Keep Going.
  • Amazon at $231: What the Filed Numbers and the Capex Commitment Imply

Read the full report on Amazon in the BullScope Terminal → It opens with this company loaded.

Edition date: 2026-08-03. This page updates when a new edition is published. Sources: SEC EDGAR filings, Nasdaq prices; computed by BullScope’s published methodology.

BullScope publishes impersonal research for a general audience. Nothing here is personalized investment advice, and nothing here is a recommendation to buy or sell any security. As of publication, neither BullScope nor its operator holds a position in any security, covered or otherwise; we do not trade at all, and we accept no compensation from any company we cover. When a conflict of interest exists, we do not publish: companies that compensate our operator in any capacity, or about which our operator could hold nonpublic information, are barred from coverage automatically, as described in the conflicts policy in our methodology. Figures come from company filings and public data through our published methodology; forecasts are conditional scenarios, not predictions and not promises. Markets carry risk, including loss of principal. Consider your own situation, or consult a licensed adviser, before acting on anything you read.
BullScope TerminalYou just read Amazon’s filed numbers.Every claim above traces to a filing. Run any of 500+ companies through the same math-vs-mood engine. Free tier available.Open the Terminal →
Moe Alsumidaie, MBA, MSF

Moe Alsumidaie, MBA, MSF

Moe Alsumidaie, MBA, MSF is the Chief Editor of BullScope. Trained in finance, with a Master of Science in Finance and an MBA, he spent years inside large public healthcare companies including Abbott, Genentech, and Roche, learning how the businesses behind the filings actually run. As a journalist and Chief Editor of The Clinical Trial Vanguard, his reporting has appeared in Applied Clinical Trials, The American Journal of Managed Care, and CNET, and has been cited in U.S. Supreme Court proceedings. At BullScope he brings those disciplines together: every note starts in the SEC filings, runs through published methodology, and shows its work.

Recommended For You

Evidence Sheet: Regeneron Pharmaceuticals (REGN)

by Moe Alsumidaie, MBA, MSF
September 9, 2026
0

The standing BullScope yardsticks for Regeneron Pharmaceuticals, computed from official filings and refreshed with each new edition.

Read moreDetails

Evidence Sheet: Viatris (VTRS)

by Moe Alsumidaie, MBA, MSF
September 8, 2026
0

The standing BullScope yardsticks for Viatris, computed from official filings and refreshed with each new edition.

Read moreDetails

Evidence Sheet: Merck & Co (MRK)

by Moe Alsumidaie, MBA, MSF
September 7, 2026
0

The standing BullScope yardsticks for Merck & Co, computed from official filings and refreshed with each new edition.

Read moreDetails

Evidence Sheet: UnitedHealth Group (UNH)

by Moe Alsumidaie, MBA, MSF
September 4, 2026
0

The standing BullScope yardsticks for UnitedHealth Group, computed from official filings and refreshed with each new edition.

Read moreDetails

Evidence Sheet: Moderna (MRNA)

by Moe Alsumidaie, MBA, MSF
September 3, 2026
0

The standing BullScope yardsticks for Moderna, computed from official filings and refreshed with each new edition.

Read moreDetails
Next Post

Meta's Q2 Filing: The Quarter the Bill Arrived

Please login to join discussion
BullScope
The Research Terminal
Run any stock through the BullScope evidence engine. Filings in, evidence out. Every number explains itself.
Open the Terminal
A BullScope product

Related News

Netflix’s Margin Story Is Winning. The Stock Has Already Forgotten.

August 18, 2026

AbbVie Reaffirms 2026 Guidance After Closing $10.9 Billion Apogee Acquisition

September 4, 2026

Evidence Sheet: Meta Platforms (META)

August 5, 2026
BullScope

BullScope is an evidence-first investment research publication. Every note starts in the filings: what companies actually report, what the market assumes, and where the two disagree. We read the numbers so you can read the story. Not investment advice.

Prefer BullScope.ai on Google

© 2026 BullScope. Evidence-first investment research. Not investment advice.  ·  Methodology  ·  Privacy Policy  ·  Terms of Use  ·  Disclaimer

No Result
View All Result
  • Home
  • Market News
  • Bargains & Bubbles
  • Expectations Audits
  • Research Notes
  • Said vs. Filed
  • The Economy
  • Evidence Sheets
  • Research Terminal

© 2026 BullScope. Evidence-first investment research. Not investment advice.  ·  Methodology  ·  Privacy Policy  ·  Terms of Use  ·  Disclaimer

Not enough quota to unlock this post
Unlock left : 0
Are you sure want to cancel subscription?
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.